These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26835148)

  • 1. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.
    Yelnik CM; Laskin CA; Porter TF; Branch DW; Buyon JP; Guerra MM; Lockshin MD; Petri M; Merrill JT; Sammaritano LR; Kim MY; Salmon JE
    Lupus Sci Med; 2016; 3(1):e000131. PubMed ID: 26835148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.
    Yelnik CM; Porter TF; Branch DW; Laskin CA; Merrill JT; Guerra MM; Lockshin MD; Buyon JP; Petri M; Sammaritano LR; Stephenson MD; Kim MY; Salmon JE
    Arthritis Rheumatol; 2016 Aug; 68(8):1964-9. PubMed ID: 26990620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
    Kim MY; Guerra MM; Kaplowitz E; Laskin CA; Petri M; Branch DW; Lockshin MD; Sammaritano LR; Merrill JT; Porter TF; Sawitzke A; Lynch AM; Buyon JP; Salmon JE
    Ann Rheum Dis; 2018 Apr; 77(4):549-555. PubMed ID: 29371202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.
    Buyon JP; Kim MY; Guerra MM; Laskin CA; Petri M; Lockshin MD; Sammaritano L; Branch DW; Porter TF; Sawitzke A; Merrill JT; Stephenson MD; Cohn E; Garabet L; Salmon JE
    Ann Intern Med; 2015 Aug; 163(3):153-63. PubMed ID: 26098843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.
    Lockshin MD; Kim M; Laskin CA; Guerra M; Branch DW; Merrill J; Petri M; Porter TF; Sammaritano L; Stephenson MD; Buyon J; Salmon JE
    Arthritis Rheum; 2012 Jul; 64(7):2311-8. PubMed ID: 22275304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis.
    Huang J; Zhu Q; Wang B; Wang H; Xie Z; Zhu X; Zhao T; Yang Z
    Expert Rev Clin Immunol; 2024 Jul; 20(7):793-801. PubMed ID: 38445835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental pathology in systemic lupus erythematosus with antiphospholipid antibodies.
    Ogishima D; Matsumoto T; Nakamura Y; Yoshida K; Kuwabara Y
    Pathol Int; 2000 Mar; 50(3):224-9. PubMed ID: 10792786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and clinical associations of lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus.
    Woo KS; Kim KE; Kim JM; Han JY; Chung WT; Kim KH
    Korean J Lab Med; 2010 Feb; 30(1):38-44. PubMed ID: 20197721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood-onset systemic lupus erythematosus: antiphospholipid antibodies in 37 patients and their first-degree relatives.
    Molta C; Meyer O; Dosquet C; Montes de Oca M; Babron MC; Danon F; Kaplan C; Clémenceau S; Castellano F; Levy M
    Pediatrics; 1993 Dec; 92(6):849-53. PubMed ID: 8233748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
    Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
    Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').
    Erton ZB; Sevim E; de Jesús GR; Cervera R; Ji L; Pengo V; Ugarte A; Andrade D; Andreoli L; Atsumi T; Fortin PR; Gerosa M; Zuo Y; Petri M; Sciascia S; Tektonidou MG; Aguirre-Zamorano MA; Branch DW; Erkan D;
    Lupus Sci Med; 2022 Jun; 9(1):. PubMed ID: 35701043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review.
    Bruce IN; Clark-Soloninka CA; Spitzer KA; Gladman DD; Urowitz MB; Laskin CA
    J Rheumatol; 2000 Dec; 27(12):2833-7. PubMed ID: 11128672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological manifestations of systemic lupus erythematosus: role of antiphospholipid antibodies.
    Golstein M; Meyer O; Bourgeois P; Palazzo E; Nicaise P; Labarre C; Kahn MF
    Clin Exp Rheumatol; 1993; 11(4):373-9. PubMed ID: 8403581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of postpartum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss.
    Clark CA; Spitzer KA; Crowther MA; Nadler JN; Laskin MD; Waks JA; Laskin CA
    J Rheumatol; 2007 May; 34(5):992-6. PubMed ID: 17407219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.